Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on CSL.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX health stocks: CSL leads another round of strong earnings, but FY22 outlook remains subdued
News
Reporting Season Round Up: Atomos leads the small caps, while Dominos stood out among large caps
Health & Biotech
This ASX-listed healthcare ETF returned 33pc in 2020 – and it’s not Blackrock’s IXJ
Health & Biotech
ScoPo’s Powerplays: ‘Lots of money on sidelines waiting for pullbacks’, as all eyes are on earnings next week
News
Here are the top ASX large cap movers for Friday
Experts
MoneyTalks: Hyperion’s top ASX stocks look big already, but here’s why they’ve got more room to grow
Health & Biotech
ScoPo’s Powerplays: Healthcare sector has bounced back as earnings season kicks off, expect to buy on the dips
Health & Biotech
Investors have struggled to find long term money makers from COVID, but has this sector been the one all along?
Health & Biotech
ScoPo’s Powerplays: Buying opportunities in a volatile week
Experts
MoneyTalks: Have you thought about your stock’s post-COVID environment? If not, this fundie thinks you should
Health & Biotech
AstraZeneca rollout in jeopardy? The ASX’s COVID vaccine maker and wannabe seem immune
News
There’s only one ASX stock involved in the COVID vaccine rollout right now; and it’s just dispatched the first doses
Experts
Scopo’s powerplays: Healthcare steadies, and Mach7 ‘looks really interesting’
Experts
ScoPo’s powerplays: It’s been a rollercoaster ride, but take a look at Neuren
Health & Biotech
AstraZeneca’s COVID-19 fight hits the skids; ASX small cap Biotron says ‘We’re on track’
Experts
Expert view: Here’s what investors are getting wrong about Australian health stocks
Experts
